Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | EPAS1 | Q99814 | 5/20 | 0.48 |
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TTK | P33981 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30987223 | 0.86 | MAPT (0.60) | KDM4EALDH1A1MAPTHSD17B10EPAS1 | |
| SCHEMBL28563540 | 0.86 | MAPT (0.60) | KDM4EALDH1A1MAPTHSD17B10EPAS1 | |
| SCHEMBL24566449 | 0.86 | MAPT (0.47) | KDM4EALDH1A1MAPTHSD17B10EPAS1 | |
| SCHEMBL28072438 | 0.84 | KDM4E (0.46) | KDM4EALDH1A1MAPTHSD17B10EPAS1 | |
| SCHEMBL29940995 | 0.84 | EPAS1 (0.54) | KDM4EALDH1A1MAPTHSD17B10EPAS1 | |
| SCHEMBL11359600 | 0.84 | ALDH1A1 (0.46) | KDM4EALDH1A1MAPTHSD17B10EPAS1 | |
| SCHEMBL24566758 | 0.82 | KDM4E (0.41) | KDM4EALDH1A1MAPTHSD17B10EPAS1 | |
| SCHEMBL21956018 | 0.81 | IDO1 (0.54) | KDM4EALDH1A1MAPTHSD17B10IDO1 | |
| SCHEMBL29737320 | 0.81 | KDM4E (0.37) | KDM4EALDH1A1MAPTHSD17B10EPAS1 | |
| SCHEMBL11352247 | 0.80 | KDM4E (0.42) | KDM4EALDH1A1MAPTHSD17B10EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157129-A1 | IRIDIUM COMPLEX AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | LUMINESCENCE TECHNOLOGY CORPORATION (TW) | 2020-05-21 | — | — | US | disclosed |
| US-20200157129-A1 | IRIDIUM COMPLEX AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | LUMINESCENCE TECHNOLOGY CORPORATION (TW) | 2020-05-21 | — | — | US | disclosed |
| US-9868722-B2 | Monocyclic pyrimidine/pyridine compounds as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| CN-105669588-B | The preparation method of benzisothiazole analog derivative | 天津大学 | 2017-11-07 | — | — | CN | disclosed |
| US-20160304495-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| CN-105669588-A | Preparation method of benzisothiazole derivative | 天津大学 | 2016-06-15 | — | — | CN | disclosed |
| EP-0946520-B1 | ISOQUINOLINAMINE AND PHTHALAZINAMINE DERIVATIVES WHICH INTERACT WITH CRF RECEPTORS | NEUROGEN CORP (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-0039795-B1 | PROCESS FOR THE PREPARATION OF 1,2-BENZISOTHIAZOLES | BASF Aktiengesellschaft (DE) | 1983-10-12 | — | — | EP | disclosed |
| EP-0039795-A1 | Process for the preparation of 1,2-benzisothiazoles | BASF Aktiengesellschaft (DE) | 1981-11-18 | — | — | EP | disclosed |
| US-4277477-A | TREATING CARDIAC ARRHYTHMIA | BASF AKTIENGESELLSCHAFT (DE) | 1981-07-07 | — | — | US | disclosed |
| EP-0000750-A1 | 1,2-Benzisothiazoles and process for their preparation | BASF Aktiengesellschaft (DE) | 1979-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157129-A1 | IRIDIUM COMPLEX AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | OPA1, MT-ND5, IMPA1 | KDM4E 3886/4885ALDH1A1 348/4885MAPT 698/4885 |
| US-20160304495-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | PSMG3, PSMD2, PSME1 | KDM4E 2933/4885ALDH1A1 2684/4885MAPT 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.